Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma
Source : https://pubmed.ncbi.nlm.nih.gov/38342727/
Strategies should be framed to address the observed disparities and to improve access.
Only 33% of African Americans lived in a county with a trial, and 7 of 10 states with the highest proportion of African American residents (18.6%-41.4%) have no or <4 trial sites.
Treatment-Specific Risk of Subsequent Malignant Neoplasms in Five-Year Survivors of Diffuse Large B-Cell Lymphoma
Source : https://pubmed.ncbi.nlm.nih.gov/38350338/
Five-year DLBCL survivors have an increased risk of SMNs. Risks were higher for survivors ≤40 years at first treatment and survivors treated with >4500 mg/m 2 cyclophosphamide/>300 mg/m 2 doxorubicin,...
Receipt of cyclophosphamide >4500 mg was associated with a 1.5-fold increased solid malignancy risk.
Vaccinations in Patients With Chronic Lymphocytic Leukemia
Source : https://www.sciencedirect.com/science/article/abs/pii/S0037196324000040?via=ihub
Chronic lymphocytic leukemia (CLL) is characterized by immune dysfunction resulting in heightened susceptibility to infections and elevated rates of m...
Humoral and cellular responses to vaccines may be discordant, and laboratory parameters are only correlates of clinical efficacy often with limited validation.
Conditional Survival to Assess Prognosis in Patients With Chronic Lymphocytic Leukemia
Source : https://link.springer.com/article/10.1007/s00277-024-05627-w
Biomarkers in chronic lymphocytic leukemia (CLL) allow assessment of prognosis. However, the validity of current prognostic biomarkers based on a single assessment point remains unclear for patients who have survived...
Researchers identified that patients with high-risk disease features such as nonmutated IGHV, deletion 17p, and high-risk CLL-IPI have a significantly worse prognosis at diagnosis, and 5-year conditional survival steadily decreases with each additional year survived.
Frequent Expression of PD-L1 In BLS-Type Diffuse Large B-Cell Lymphoma: Implications for Aggressiveness and Immunotherapy
Source : https://pubmed.ncbi.nlm.nih.gov/38290893/
BLS-type diffuse large B-cell lymphoma (DLBCL) denotes an uncommon, aggressive variant of DLBCL presenting initially in bone marrow, liver and spleen without lymphadenopathy or mass lesion. Patients with BLS-type DLBCL...
Researchers found that found that PD-L1 was positive in 12.9% of DLBCL-NOS cases, 46.2% of EBV-positive DLBCL, 91.7% of thymic LBCL, 8.3% of high-grade B-cell lymphoma-NOS, and 56.8% of BLS-type DLBCL.